Deqing, China, May 28, 2018 / B3C newswire / -- Shuwen Biotech Co. Ltd., an emerging leader in innovative diagnostic products and services announced today it has signed a partnership agreement with Bliss Biopharmaceutical Co., Ltd., a biopharmaceutical company engaged in the discovery, development and commercialization of biotherapeutics for unmet medical needs.
Under the agreement, Shuwen will develop companion diagnostics for Bliss’ oncology drug candidates. Shuwen also commits to provide testing services in its CAP-certified central labs for BlissBio’ clinical trials. The terms of the collaboration are undisclosed.
“Companion diagnostics and precision medicine are Shuwen’s major focus. We have partnered with a number of pharmaceutical companies. This collaboration will fuel continued innovation by BlissBio and further demonstrate how Shuwen can deliver value through its strong companion diagnostics development team and its CAP-accredited lab facilities,” said Jay Z. Zhang, Shuwen’s Chairman and Chief Executive Officer.
“We have some of the best-in-class biologics in development. Shuwen provides versatile technologies that may enable the precise selection of the most suitable patients for our drug candidates, thus increasing the competitiveness of our products. We are very happy to work with Shuwen,” commented Dr. Ziping Wei, BlissBio’ Chief Executive Officer.
About Shuwen Biotech
Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, BioNTech, Sphingotec among others in the form of exclusive licensing of first-in-class diagnostic technologies and patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.
About Bliss Biopharmaceutical
Bliss Biopharmaceutical (Hangzhou) Co. Ltd. (BlissBio) is a biopharmaceutical company focusing on discovery, development and commercialization of biotherapeutics for unmet medical needs. It is located in the high-tech enterprises in Hangzhou Economic and Technological Development Park in Hangzhou, China, and jointly established by a number of biopharmaceutical leaders returned to China from overseas, each with over 20 years of industrial experience. Its mission is to unite and bring to life the ideas and strengths of hundreds of collaborators to advance product pipeline and improve human health. The company has developed a rich pipeline engaging multiple technology platforms through collaborations with domestic and foreign biopharmaceutical companies. BlissBio has completed its first round of financing, and is rapidly advancing multiple products through different development stages.